以氨苯砜综合征为模型解析药物超敏反应中的免疫失衡

doi:10.35541/cjd.20260100

Abstract

Abstract: 【Abstract】 Drug hypersensitivity is a severe adverse drug reaction characterized by a prolonged latency period, complex clinical manifestations, and a potentially life-threatening course. In this article, dapsone hypersensitivity syndrome serves as a model for dissecting the roles of genetic predisposition, innate immunity, and acquired immunity in the development of drug hypersensitivity. Based on this model, key unresolved challenges in the prevention, diagnosis, and treatment of drug hypersensitivity are proposed, and a multifactorial risk prediction model is expected to be established to guide the prevention of drug hypersensitivity.

Key words: Drug-related side effects and adverse reactions, Hypersensitivity, delayed, Dapsone, Dapsone hypersensitivity syndrome, Pharmacogenomic testing, Killer cells, natural, Tumor necrosis factor-alpha, Precision medicine

Zhao Qing, Sun Lele, Ao Suiting, Zhai Yufan, Liu Hong, Zhang Furen. Analysis of immune dysregulation in drug hypersensitivity by using dapsone hypersensitivity syndrome as a model[J]. Chinese Journal of Dermatology, 2026, 59(9): 844-849.doi:10.35541/cjd.20260100

References ［47］

［1］	Kroshinsky D, Cardones A, Blumenthal KG. Drug reaction with eosinophilia and systemic symptoms［J］. N Engl J Med, 2024,391（23）:2242⁃2254. DOI: 10.1056/NEJMra2204547.
［2］	Hung SI, Mockenhaupt M, Blumenthal KG, et al. Severe cutaneous adverse reactions［J］. Nat Rev Dis Primers, 2024,10（1）:30. DOI: 10.1038/s41572⁃024⁃00514⁃0.
［3］	Komatsu⁃Fujii T, Kaneko S, Chinuki Y, et al. Serum TARC levels are strongly correlated with blood eosinophil count in patients with drug eruptions［J］. Allergol Int, 2017,66（1）:116⁃122. DOI: 10.1016/j.alit.2016.06.003.
［4］	Ogawa K, Morito H, Hasegawa A, et al. Identification of thymus and activation⁃regulated chemokine （TARC/CCL17） as a potential marker for early indication of disease and prediction of disease activity in drug⁃induced hypersensitivity syndrome （DIHS）/drug rash with eosinophilia and systemic symptoms （DRESS）［J］. J Dermatol Sci, 2013,69（1）:38⁃43. DOI: 10.1016/j.jdermsci.2012.10.002.
［5］	Musette P, Janela B. New insights into drug reaction with eosinophilia and systemic symptoms pathophysiology［J］. Front Med （Lausanne）, 2017,4:179. DOI: 10.3389/fmed.2017.00179.
［6］	Dubin DP, Yassky D, Poplausky D, et al. Dupilumab to treat drug reaction with eosinophilia and systemic symptoms: a case series［J］. J Allergy Clin Immunol Pract, 2023,11（12）:3789⁃3791. DOI: 10.1016/j.jaip.2023.08.028.
［7］	Rubin L, Talmon A, Ribak Y, et al. Novel targeted inhibition of the IL⁃5 axis for drug reaction with eosinophilia and systemic symptoms syndrome［J］. Front Immunol, 2023,14:1134178. DOI: 10.3389/fimmu.2023.1134178.
［8］	Hama N, Abe R, Gibson A, et al. Drug⁃induced hypersensitivity syndrome （DIHS）/drug reaction with eosinophilia and systemic symptoms （DRESS）: clinical features and pathogenesis［J］. J Allergy Clin Immunol Pract, 2022,10（5）:1155⁃1167. DOI: 10.1016/j.jaip.2022.02.004.
［9］	Chung WH, Hung SI, Yang JY, et al. Granulysin is a key mediator for disseminated keratinocyte death in Stevens⁃Johnson syndrome and toxic epidermal necrolysis［J］. Nat Med, 2008,14（12）:1343⁃1350. DOI: 10.1038/nm.1884.
［10］	Viard⁃Leveugle I, Gaide O, Jankovic D, et al. TNF⁃α and IFN⁃γ are potential inducers of Fas⁃mediated keratinocyte apoptosis through activation of inducible nitric oxide synthase in toxic epidermal necrolysis［J］. J Invest Dermatol, 2013,133（2）:489⁃498. DOI: 10.1038/jid.2012.330.
［11］	Abe R, Shimizu T, Shibaki A, et al. Toxic epidermal necrolysis and Stevens⁃Johnson syndrome are induced by soluble Fas ligand［J］. Am J Pathol, 2003,162（5）:1515⁃1520. DOI: 10.1016/S0002⁃9440（10）64284⁃8.
［12］	Nassif A, Bensussan A, Boumsell L, et al. Toxic epidermal necrolysis: effector cells are drug⁃specific cytotoxic T cells［J］. J Allergy Clin Immunol, 2004,114（5）:1209⁃1215. DOI: 10.1016/j.jaci.2004.07.047.
［13］	Cadot R, Gery P, Lenief V, et al. Exploring recent advances in drugs severe cutaneous adverse reactions immunopathology［J］. Allergy, 2025,80（1）:47⁃62. DOI: 10.1111/all.16316.
［14］	Umayahara T, Shimauchi T, Fujiyama T, et al. Paediatric acute generalized exanthematous pustulosis induced by paracetamol with high serum levels of interleukin⁃8 and ⁃22: a case report［J］. Acta Derm Venereol, 2013,93（3）:362⁃363. DOI: 10.2340/00015555⁃1462.
［15］	Britschgi M, Pichler WJ. Acute generalized exanthematous pustulosis, a clue to neutrophil⁃mediated inflammatory processes orchestrated by T cells［J］. Curr Opin Allergy Clin Immunol, 2002,2（4）:325⁃331. DOI: 10.1097/00130832⁃200208000⁃00006.
［16］	Marwa K, Goldin J, Kondamudi NP. TypeⅣ hypersensitivity reaction［M/OL］. Treasure Island （FL）: StatPearls Publishing, 2025［2026⁃02⁃26］. https://www.ncbi.nlm.nih.gov/books/NBK562228/.
［17］	Kardaun SH, Sekula P, Valeyrie⁃Allanore L, et al. Drug reaction with eosinophilia and systemic symptoms （DRESS）: an original multisystem adverse drug reaction. results from the prospective regiSCAR study［J］. Br J Dermatol, 2013,169（5）:1071⁃1080. DOI: 10.1111/bjd.12501.
［18］	Sun L, Huai P, Wang Z, et al. TSC22 domain family member 3 links natural killer cells to CD8+ T cell⁃mediated drug hypersensitivity［J］. Signal Transduct Target Ther, 2025,10（1）:196. DOI: 10.1038/s41392⁃025⁃02300⁃0.
［19］	Zhang FR, Liu H, Irwanto A, et al. HLA⁃B*13:01 and the dapsone hypersensitivity syndrome［J］. N Engl J Med, 2013,369（17）:1620⁃1628. DOI: 10.1056/NEJMoa1213096.
［20］	Lowe J, Smith M. The chemotherapy of leprosy in Nigeria; with an appendix on glandular fever and exfoliative dermatitis precipitated by sulfones［J］. Int J Lepr, 1949,17（3）:181⁃195.
［21］	Allday EJ, Barnes J. Toxic effects of diaminodiphenylsulphone in treatment of leprosy［J］. Lancet, 1951,2（6675）:205⁃206. DOI: 10.1016/s0140⁃6736（51）91443⁃2.
［22］	Wozel G, Blasum C. Dapsone in dermatology and beyond［J］. Arch Dermatol Res, 2014,306（2）:103⁃124. DOI: 10.1007/s00403⁃013⁃1409⁃7.
［23］	Maddala RR, Ghorpade A, Adulkar S, et al. Anatopic response: double sparing phenomenon in a patient with dapsone hypersensitivity syndrome［J］. Indian J Dermatol Venereol Leprol, 2017,83（2）:241⁃243. DOI: 10.4103/0378⁃6323.193609.
［24］	Lorenz M, Wozel G, Schmitt J. Hypersensitivity reactions to dapsone: a systematic review［J］. Acta Derm Venereol, 2012,92（2）:194⁃199. DOI: 10.2340/00015555⁃1268.
［25］	do Valle SO, França AT, Pires GV, et al. Dapsone hypersensitivity syndrome during delayed pressure urticaria treatment［J］. Ann Allergy Asthma Immunol, 2010,104（2）:181⁃182. DOI: 10.1016/j.anai.2009.11.041.
［26］	Zhu KJ, He FT, Jin N, et al. Complete atrioventricular block associated with dapsone therapy: a rare complication of dapsone⁃induced hypersensitivity syndrome［J］. J Clin Pharm Ther, 2009,34（4）:489⁃492. DOI: 10.1111/j.1365⁃2710.2008.00991.x.
［27］	Takahashi H, Tanaka M, Tanikawa A, et al. A case of drug⁃induced hypersensitivity syndrome showing transient immunosuppression before viral reactivation during treatment for pemphigus foliaceus［J］. Clin Exp Dermatol, 2006,31（1）:33⁃35. DOI: 10.1111/j.1365⁃2230.2005.01913.x.
［28］	Grace M. An unusual case of dapsone syndrome［J］. Indian Dermatol Online J, 2011,2（2）:88⁃90. DOI: 10.4103/2229⁃5178.85999.
［29］	Hirahara K, Kano Y, Asano Y, et al. Osteonecrosis of the femoral head in a patient with henoch⁃schönlein purpura and drug⁃induced hypersensitivity syndrome treated with corticosteroids［J］. Acta Derm Venereol, 2013,93（1）:85⁃86. DOI: 10.2340/00015555⁃1417.
［30］	Thong BY, Leong KP, Chng HH. Hypersensitivity syndrome associated with dapsone/pyrimethamine （maloprim） antimalaria chemoprophylaxis［J］. Ann Allergy Asthma Immunol, 2002,88（5）:527⁃529. DOI: 10.1016/S1081⁃1206（10）62394⁃0.
［31］	Roth M, Gray JT, Peterson PG, et al. Dapsone⁃induced DRESS after infliximab⁃induced vasculitis: a case of cerebral infarction in the context of multiple drug reactions［J］. BMJ Case Rep, 2020,13（12）:237560. DOI: 10.1136/bcr⁃2020⁃237560.
［32］	Kinehara Y, Kijima T, Inoue K, et al. Dapsone hypersensitivity syndrome⁃related lung injury without eosinophilia in the bronchoalveolar lavage fluid［J］. Intern Med, 2015,54（7）:827⁃831. DOI: 10.2169/internalmedicine.54.3406.
［33］	Chen WT, Wang CW, Lu CW, et al. The function of HLA⁃B*13:01 involved in the pathomechanism of dapsone⁃induced severe cutaneous adverse reactions［J］. J Invest Dermatol, 2018,138（7）:1546⁃1554. DOI: 10.1016/j.jid.2018.02.004.
［34］	Zhao Q, Alhilali K, Alzahrani A, et al. Dapsone⁃ and nitroso dapsone⁃specific activation of T cells from hypersensitive patients expressing the risk allele HLA⁃B*13:01［J］. Allergy, 2019,74（8）:1533⁃1548. DOI: 10.1111/all.13769.
［35］	Watanabe H, Watanabe Y, Tashiro Y, et al. A docking model of dapsone bound to HLA⁃B*13:01 explains the risk of dapsone hypersensitivity syndrome［J］. J Dermatol Sci, 2017,88（3）:320⁃329. DOI: 10.1016/j.jdermsci.2017.08.007.
［36］	Yue Z, Sun Y, Wang C, et al. Amino acid variants of HLA⁃DRB1 confer susceptibility to dapsone hypersensitivity syndrome in addition to HLA⁃B*13:01［J］. J Invest Dermatol, 2018,138（5）:1101⁃1106. DOI: 10.1016/j.jid.2017.11.027.
［37］	Zhao Q, Almutairi M, Tailor A, et al. HLA class⁃2⁃restricted CD8+ T cells contribute to the promiscuous immune response in dapsone⁃hypersensitive patients［J］. J Invest Dermatol, 2021,141（10）:2412⁃2425.e2. DOI: 10.1016/j.jid.2021.03.014.
［38］	Jiang H, Wang CW, Wang Z, et al. Functional and structural characteristics of HLA⁃B*13:01⁃mediated specific T cells reaction in dapsone⁃induced drug hypersensitivity［J］. J Biomed Sci, 2022,29（1）:58. DOI: 10.1186/s12929⁃022⁃00845⁃8.
［39］	Sun L, Wang Z, Liu T, et al. TAP2 drives HLA⁃B∗13:01‒linked dapsone hypersensitivity syndrome tolerance and reactivity［J］. J Invest Dermatol, 2023,143（5）:722⁃730. DOI: 10.1016/j.jid. 2022.10.009.
［40］	Ao S, Gao X, Zhan J, et al. Inhibition of tumor necrosis factor improves conventional steroid therapy for Stevens⁃Johnson syndrome/toxic epidermal necrolysis in a cohort of patients［J］. J Am Acad Dermatol, 2022,86（6）:1236⁃1245. DOI: 10.1016/j.jaad.2022.01.039.
［41］	Chen X, Bäumel M, Männel DN, et al. Interaction of TNF with TNF receptor type 2 promotes expansion and function of mouse CD4+CD25+ T regulatory cells［J］. J Immunol, 2007,179（1）:154⁃161. DOI: 10.4049/jimmunol.179.1.154.
［42］	Inoue M, Tsuji Y, Yoshimine C, et al. Structural optimization of a TNFR1⁃selective antagonistic tnfα mutant to create new⁃modality TNF⁃regulating biologics［J］. J Biol Chem, 2020,295（28）:9379⁃9391. DOI: 10.1074/jbc.RA120.012723.
［43］	Xue R, Li G, Zhou Y, et al. Efficacy and safety of low⁃dose interleukin 2 in the treatment of moderate⁃to⁃severe bullous pemphigoid: a single center perspective⁃controlled trial［J］. J Am Acad Dermatol, 2024,91（6）:1113⁃1117. DOI: 10.1016/j.jaad.2024.08.033.
［44］	Sun L, Zhao Q, Ao S, et al. Feedback regulation of VISTA and Treg by TNF⁃α controls T cell responses in drug allergy［J］. Allergy, 2025,80（5）:1400⁃1416. DOI: 10.1111/all.16393.
［45］	Campbell CN, Krantz MS, Yu A, et al. HLA⁃B*58:01 and risk of allopurinol⁃induced severe cutaneous adverse reactions in the US［J］. JAMA Dermatol, 2025,161（12）:1258⁃1263. DOI: 10.1001/jamadermatol.2025.4240.
［46］	Pan RY, Chu MT, Wang CW, et al. Identification of drug⁃specific public TCR driving severe cutaneous adverse reactions［J］. Nat Commun, 2019,10（1）:3569. DOI: 10.1038/s41467⁃019⁃11396⁃2.
［47］	Aggarwal R, Sharma M, Modi M, et al. HLA⁃B∗ 1502 is associated with carbamazepine induced Stevens⁃Johnson syndrome in north Indian population［J］. Hum Immunol, 2014,75（11）:1120⁃1122. DOI: 10.1016/j.humimm.2014.09.022.

[1]	Chinese Society of Dermatology, Chinese Society of Allergy, China Leprosy Association. Chinese guideline for the diagnosis and treatment of drug eruptions （2026 edition） [J]. Chinese Journal of Dermatology, 2026, 59(9): 811-826.
[2]	Li Yanhong, Jiang Kun, Wu Zhuoxuan, Zhang Jianlan, Fang Meizhen, Liu Shuting, Wang Linlin, Hu Lei, Zhou Xiaoyong, Chen Liuqing, Chen Jinbo. Analysis of 18 cases of cutaneous adverse reactions associated with programmed death-1 inhibitors [J]. Chinese Journal of Dermatology, 2026, 59(8): 783-787.
[3]	Zhang Xiaoxu, Luo Suju. Efficacy and safety of upadacitinib in the treatment of six cases of palmoplantar pustulosis [J]. Chinese Journal of Dermatology, 2026, 59(5): 459-463.
[4]	Committee on Skin Disease and Cosmetic Dermatology, China Association of Medical Equipment, Patient Education Expert Committee, Chinese Society of Clinical Oncology . Chinese expert consensus on multidisciplinary management of cancer treatment-related cutaneous adverse events （2026 edition） [J]. Chinese Journal of Dermatology, 2026, 59(4): 304-319.
[5]	Xu Guokang, Cai Mei. Sonidegib in the treatment of locally advanced basal cell carcinoma: a clinical analysis of eight cases [J]. Chinese Journal of Dermatology, 2026, 59(2): 166-169.
[6]	Zhang Fengyuan, Chen Sihan, Zhou Zizhen, Zhou Meng, Zeng Rong, Chen Xu, Lian Ni, Li Min. Cutibacterium acnes promotes inflammation in acne by inducing Gasdermin E-mediated pyroptosis in keratinocytes [J]. Chinese Journal of Dermatology, 2025, 58(7): 623-629.
[7]	Qiu Li, Xiao Ting . Bruton′s tyrosine kinase inhibitors in the treatment of chronic spontaneous urticaria [J]. Chinese Journal of Dermatology, 2025, 58(6): 563-567.
[8]	Ye Ruixian, Xue Rujun, Liang Jingyao, Zhang Xibao. Circ_0086376 targeted miR-5195-3p to regulate the expression of inflammatory factors mediated by Propionibacterium acnes in HaCaT cells [J]. Chinese Journal of Dermatology, 2025, 58(4): 340-346.
[9]	Wan Yongjun, Yang Haijing, Yan Qiao, Chen Mei, Wang Fengyuan, Su Qianya, Dong Zhengbang, Wang Fei. Clinical and prognostic analysis of nine cases of immune checkpoint inhibitor-related Stevens-Johnson syndrome/toxic epidermal necrolysis [J]. Chinese Journal of Dermatology, 2025, 58(4): 347-351.
[10]	Mu Kui, Guo Hui, Wen Haiquan, Long Hai, Liu Yu, Luo Shuaihantian, Huang Xin, Zhou Xingyu, Xiao Rong, Li Yaping. Efficacy and safety analysis of combined telitacicept in 25 patients with systemic lupus erythematosus based on standard therapy [J]. Chinese Journal of Dermatology, 2025, 58(4): 322-327.
[11]	Pi Jiangshan, Chen Jingsi, Wang Lingling, Shen Zhanting, Luo Xiaoyan, Wang Hua. Efficacy and safety of dupilumab in the treatment of moderate-to-severe atopic dermatitis in infants aged 6 months to 2 years: a prospective, single-center clinical trial [J]. Chinese Journal of Dermatology, 2025, 58(10): 930-935.
[12]	Jin Lan, Qiu Yun, Wang Weijia, Kang Xiaojing, Ding Yuan. Clinical efficacy and safety of biological agents in the treatment of moderate-to-severe psoriasis in 124 elderly patients: a retrospective analysis [J]. Chinese Journal of Dermatology, 2025, 58(1): 47-52.
[13]	Wang Bo, Zheng Jie. Considerations in the treatment of elderly patients with psoriasis and atopic dermatitis using biologics and small-molecule drugs [J]. Chinese Journal of Dermatology, 2025, 58(1): 72-75.
[14]	Yang Zijing, Chen Lihong, Ruan Yeping, Wen Wanting, Zhang Jiayi, Wang Hailun, Pan Meng, Zhao Xiaoqing. Efficacy and safety of dupilumab in the treatment of atopic dermatitis in the elderly [J]. Chinese Journal of Dermatology, 2025, 58(1): 65-69.
[15]	Jing Ke, Li Suo, Feng Suying. Clinical and immunoserological characteristics of 26 cases of linear IgA bullous dermatosis: a retrospective analysis [J]. Chinese Journal of Dermatology, 2024, 57(6): 503-509.

Analysis of immune dysregulation in drug hypersensitivity by using dapsone hypersensitivity syndrome as a model

PDF

Knowledge

Abstract

Cite this article

share this article

References ［47］

Related Articles 15

Metrics

Comments

Recommended 0